Why Medpace (MEDP) Stock Is Trading Lower Today

What Happened?

Shares of clinical research company Medpace Holdings (NASDAQ:MEDP) fell 3.2% in the morning session after Barclays downgraded the stock to "Underweight" from "Equal-Weight" and reduced its price target. 

The firm's analyst, Luke Sergott, adjusted the price target for Medpace down to $425 from $450. An "Underweight" rating typically suggests an analyst believed the stock would likely underperform the average return of other stocks covered by the analyst. The downgrade came amid a broader observation that the life science tools subsector was among the most under-owned areas within healthcare, which could limit investor interest in the space.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Medpace? Access our full analysis report here, it’s free.

What Is The Market Telling Us

Medpace’s shares are quite volatile and have had 17 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The biggest move we wrote about over the last year was 2 months ago when the stock gained 49.3% on the news that the company reported strong second-quarter financial results and raised its full-year guidance. 

The company announced its second-quarter results, revealing revenue of $603.3 million, a 14.2% increase from the prior-year period. Earnings per share also grew, coming in at $3.10. Following the strong performance, Medpace raised its full-year 2025 revenue forecast to a range of $2.42 billion to $2.52 billion. It also increased its earnings per share guidance for the year to a range of $13.76 to $14.53. This positive outlook, which surpassed previous forecasts, appeared to fuel significant investor optimism. Medpace, which provides services for all phases of clinical drug development, was scheduled to host a conference call to discuss the results.

Medpace is up 58.1% since the beginning of the year, and at $529.16 per share, it is trading close to its 52-week high of $543.90 from September 2025. Investors who bought $1,000 worth of Medpace’s shares 5 years ago would now be looking at an investment worth $4,601.

Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free and will only take you a second.